BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PAM50
11 results:

  • 1. Bioinformatics analysis of the clinicopathological and prognostic significance of BAG3 mRNA in gynecological cancers.
    Wang ZM; Zhang L; Ren DH; Zhang CY; Zheng HC
    J Obstet Gynaecol; 2023 Dec; 43(2):2228899. PubMed ID: 37377218
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A bioinformatics analysis of the clinicopathological and prognostic significance of
    Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
    J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
    Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
    J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.
    E Y; Xue H; Zhang CY; Zhao MZ; Zheng HC
    Histol Histopathol; 2023 Apr; 38(4):453-465. PubMed ID: 36255176
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types.
    Guerrero-Gimenez ME; Fernandez-Muñoz JM; Lang BJ; Holton KM; Ciocca DR; Catania CA; Zoppino FCM
    Bioinformatics; 2020 Dec; 36(20):5037-5044. PubMed ID: 32638009
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
    Feng X; Tang R; Zhang R; Wang H; Ji Z; Shao Y; Wang S; Zhong T; Gu Y; Meng J
    J Cell Mol Med; 2020 May; 24(9):5238-5248. PubMed ID: 32227579
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
    Zhao SG; Chen WS; Das R; Chang SL; Tomlins SA; Chou J; Quigley DA; Dang HX; Barnard TJ; Mahal BA; Gibb EA; Liu Y; Davicioni E; Duska LR; Posadas EM; Jolly S; Spratt DE; Nguyen PL; Maher CA; Small EJ; Feng FY
    Clin Cancer Res; 2019 Apr; 25(8):2450-2457. PubMed ID: 30573691
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
    Laurberg T; Tramm T; Nielsen T; Alsner J; Nord S; Myhre S; Sørlie T; Leung S; Fan C; Perou C; Gelmon K; Overgaard J; Voduc D; Prat A; Cheang MCU
    Acta Oncol; 2018 Jan; 57(1):38-43. PubMed ID: 29172851
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Biomarkers in Breast cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
    Prat A; Cruz C; Hoadley KA; Díez O; Perou CM; Balmaña J
    Breast Cancer Res Treat; 2014 Aug; 147(1):185-91. PubMed ID: 25048467
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.
    Abdel-Fatah TM; Russell R; Albarakati N; Maloney DJ; Dorjsuren D; Rueda OM; Moseley P; Mohan V; Sun H; Abbotts R; Mukherjee A; Agarwal D; Illuzzi JL; Jadhav A; Simeonov A; Ball G; Chan S; Caldas C; Ellis IO; Wilson DM; Madhusudan S
    Mol Oncol; 2014 Oct; 8(7):1326-38. PubMed ID: 24880630
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.